Piper Jaffray analyst Christopher Raymond maintained an Overweight rating and $180 price target on Alexion (ALXN) in a note titled "Positive P2 Danicopan PNH Update; P3 Initiation Expected in Early 2020." The analyst viewed the topline Phase 2 data on Achillion's (ACHN) Danicopan in combination with Soliris as "yet another supportive data point" for his hypothesis that combining the two drug therapies "makes sense." Raymond noted that Alexion's acquisition of Achillion is on track to close in the first half of 2020, and he was positive on how Alexion is broadening and diversifying its portfolio.